Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 July 2023 | Story Dr Anchen Froneman | Photo Supplied
Odeion
Odeion School of Music (OSM) at the University of the Free State (UFS) will offer two new qualifications, namely the Advanced Diploma in Opera Studies and the Postgraduate Diploma in Music Performance from next year.

Over the past decade, the Odeion School of Music (OSM) at the University of the Free State (UFS) has been active in designing new qualifications and restructuring current offerings. The OSM introduced the Higher Certificate in Music Performance (in 2017) and a restructured Diploma in Music in 2018 to admit students without the necessary admission requirements for degree studies and develop the necessary skills in that regard. The purpose of these qualifications was to promote inclusivity in providing access to tertiary studies to students who developed musical skills at a more mature age for the first time. 

From next year, OSM will offer two new qualifications, namely the Advanced Diploma in Opera Studies and the Postgraduate Diploma in Music Performance. Applications are currently open and will close on 30 September. Classes will commence in February 2024. 

Dr Anchen Froneman, Programme Director and Senior Lecturer at OSM, says since the commencement of the Higher Certificate in Music Performance (in 2017) and the restructured Diploma in Music, the student intake included a high number of talented vocalists or late-developing instrumentalists. Many students in these programmes were already in their 20s, but through these programmes could develop their inherent talents and passions. Upon finishing the Diploma in Music, the students could then enter a degree qualification in music studies.

“However, the degree programmes are academically oriented while the Higher Certificate in Music Performance and Diploma in Music are vocational in nature. This disjunction led to the design of the Advanced Diploma in Opera Studies to provide a programme through which the students can access a NQF 7 level qualification in a shorter time than the current existing route through the degree programmes that requires another three or four years of study,” says Dr Froneman. 

The Advanced Diploma in Opera Studies

According to her, the Advanced Diploma in Opera Studies aims to prepare students completing the Diploma of Music for professional practice within a single academic year. This specialisation option attempts to enable students with the skillset to partake in Opera productions both locally and internationally as well as to develop an understanding of operatic activities within local communities and specifically to continuously develop young talent for future operatic careers. The modules in the programme include Performance Studies, Vocal Ensemble, Stage Craft and Language for Singers. To serve the teaching duties which are often carried out simultaneously with an operatic career, the modules of Repertoire and Method and Keyboard Skills are included. The Arts Management module serves the management of a professional opera and/or teaching career. The Introduction to Research Skills develops research and academic writing skills in view of possible further postgraduate studies. 

The Postgraduate Diploma in Music Performance

The Postgraduate Diploma in Music Performance, explains Dr Froneman, is a one-year qualification but has dual aims. Firstly, the programme will add to the offerings of the UFS that aims to widen access to tertiary education, especially considering the linear progression within vertical articulation possibilities from the Higher Certificate in Music Performance to the Diploma in Music, followed by the Advanced Diploma in Opera Studies that can eventually lead to the PGDip (Music Performance). Secondly, this qualification is partly directed at individuals with active careers in the music industry (both public and private sectors) who wish to advance performance skills and research ability. The qualification is designed to make a positive contribution towards expanding existing career opportunities for individuals completing the qualification. 

The ability to present two public concerts of high quality as a soloist or chamber musician will be developed using two recital modules. The Main Recital comprises of an approved programme 35 to 45 minutes (for vocalists and brass instruments) or 60 to 70 minutes (for all other instruments) as well as a Short Recital comprising an approved programme approximately 20 minutes (for vocalists and brass instruments) or 30 minutes (for all other instruments). Performance experts oversee and guide the preparation for these public concerts. The Viva Voce module will develop and evaluate a student’s ability to critically reflect upon and discuss musical works presented during the Main Recital.

The expert musician supervising the recital modules oversees this process in which understanding is fostered through practical experience, research, and application. The Structure Research Essay develops the student’s ability to contribute to performance-related scholarship by applying appropriate research methods and writing skills to reflect upon performance practices in, amongst others, historical, analytical, cultural, social or pedagogical aspects.

For more information on these qualifications and applications, please contact: 

Dr Anchen Froneman 
Programme Director and Senior Lecturer: Odeion School of Music 
Faculty: The Humanities
+27 51 401 2526

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept